

## **Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines**

### **Fuse Science, Inc.**

25 N Market St Office 115

Jacksonville, FL 32202

929.209.2028

<https://www.deskx.ai>

[ir@kustomeroo.com](mailto:ir@kustomeroo.com)

4581

Annual Report For the Period Ending: September 30 2022  
(the "Reporting Period")

As of September 30, 2022 the number of shares outstanding of our Common Stock was 800,000,000

As of June 30, 2022 the number of shares outstanding of our Common Stock was 80,000,000

As of September 30, 2021 the number of shares outstanding of our Common Stock was 80,000,000

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Indicate by check mark whether a Change in Control<sup>5</sup> of the company has occurred over this reporting period:

Yes: ☐ No: ☒

---

<sup>5</sup> "Change in Control" shall mean any events resulting in:

- (i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

**1) Name and address(es) of the issuer and its predecessors (if any)**

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

Fuse Science, Inc.

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

Nevada : active

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

none

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

none

The address(es) of the issuer's principal executive office:

25 N Market St Office 115 Jacksonville, FL 32202

The address(es) of the issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address: ☒

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ☐ No: ☒

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

**2) Security Information**

Trading symbol: DROP  
Exact title and class of securities outstanding: Common  
CUSIP: 36113J304  
Par or stated value: .001

Total shares authorized: 800,000,000 as of date: September 30 2022  
Total shares outstanding: 80,000,000 as of date: September 30 2022

Number of shares in the Public Float<sup>6</sup>: 69,413,542 as of date: September 30 2022  
Total number of shareholders of record: 69 as of date: September 30 2022

All additional class(es) of publicly traded securities (if any):

Trading symbol: DROP  
Exact title and class of securities outstanding: common  
CUSIP: 36113J304  
Par or stated value: .001  
Total shares authorized: 800,000,000 as of date: September 30 2022  
Total shares outstanding: 80,000,000 as of date: September 30 2022

#### Transfer Agent

Name: Equity Stock Transfer  
Phone: 212-575-5757  
Email:  
Address: 237 W 37th St #602 New York, NY 10018

Is the Transfer Agent registered under the Exchange Act?<sup>7</sup> Yes: ☒ No: ☐

### 3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

#### A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: ☒

| Shares Outstanding as of Second Most Recent Fiscal Year End:<br><u>Opening Balance</u><br>Date _____ Common: _____<br>Preferred: _____ |  |  | *Right-click the rows below and select "Insert" to add rows as needed. |                                |   |   |   |   |                                 |
|--|--|--|--|--------------------------------|---|---|---|---|---------------------------------|
| Date of Transaction  | Transaction type (e.g. new issuance, cancellation, shares) | Number of Shares Issued (or cancelled) | Class of Securities  | Value of shares issued (\$/per | Were the shares issued at a discount to market price at | Individual/ Entity Shares were issued to (entities must have individual with voting / | Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of | Restricted or Unrestricted as of this filing. | Exemption or Registration Type. |

<sup>6</sup> "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

<sup>7</sup> To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

|  | returned to treasury) |                |       | share) at Issuance | the time of issuance? (Yes/No) | investment control disclosed). | Services Provided |       |       |  |  |  |  |  |  |  |
|--|-----------------------|----------------|-------|--------------------|--------------------------------|--------------------------------|-------------------|-------|-------|--|--|--|--|--|--|--|
| _____                                      | _____                 | _____          | _____ | _____              | _____                          | _____                          | _____             | _____ | _____ |  |  |  |  |  |  |  |
| _____                                      | _____                 | _____          | _____ | _____              | _____                          | _____                          | _____             | _____ | _____ |  |  |  |  |  |  |  |
| _____                                      | _____                 | _____          | _____ | _____              | _____                          | _____                          | _____             | _____ | _____ |  |  |  |  |  |  |  |
| Shares Outstanding on Date of This Report: |                       |                |       |                    |                                |                                |                   |       |       |  |  |  |  |  |  |  |
|  | <u>Ending</u> _____   | <u>Balance</u> |       |                    |                                |                                |                   |       |       |  |  |  |  |  |  |  |
| <u>Ending Balance:</u>                     |                       |                |       |                    |                                |                                |                   |       |       |  |  |  |  |  |  |  |
| Date _____                                 | Common: _____         |                |       |                    |                                |                                |                   |       |       |  |  |  |  |  |  |  |
|  | Preferred: _____      |                |       |                    |                                |                                |                   |       |       |  |  |  |  |  |  |  |

**Example:** A company with a fiscal year end of December 31<sup>st</sup>, in addressing this item for its quarter ended June 30, 2021, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2019 through June 30, 2021 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

\_\_\_\_\_

## B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements: ☐

| Date of<br>Note<br>Issuance | Outstanding<br>Balance (\$) | Principal<br>Amount<br>at<br>Issuance<br>(\$) | Interest<br>Accrued<br>(\$) | Maturity<br>Date | Conversion Terms (e.g.<br>pricing mechanism for<br>determining conversion of<br>instrument to shares) | Name of Noteholder<br>(entities must have<br>individual with voting<br>/ investment control<br>disclosed). | Reason for<br>Issuance (e.g.<br>Loan, Services,<br>etc.) |
|-----------------------------|-----------------------------|---|-----------------------------|------------------|---|--|--|
| _____                       | _____                       | _____   | _____                       | _____            | _____   | _____  | _____  |
| _____                       | _____                       | _____   | _____                       | _____            | _____   | _____  | _____  |
| _____                       | _____                       | _____   | _____                       | _____            | _____   | _____  | _____  |
| _____                       | _____                       | _____   | _____                       | _____            | _____   | _____  | _____  |

Use the space below to provide any additional details, including footnotes to the table above:

\_\_\_\_\_

#### 4) Financial Statements

A. The following financial statements were prepared in accordance with:

- ☒ U.S. GAAP  
☐ IFRS

B. The financial statements for this reporting period were prepared by (name of individual)<sup>8</sup>:

Name: Esau David Delke  
Title: CEO  
Relationship to Issuer: CEO

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance Sheet;
- D. Statement of Income;
- E. Statement of Cash Flows;
- F. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- G. Financial notes; and
- H. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

---

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

#### 5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

Company operates a cloud based customer service software platform for business of all sizes.

---

<sup>8</sup> The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

B. Please list any subsidiaries, parents, or affiliated companies.

None

C. Describe the issuers' principal products or services.

cloud based customer service software platform

## 6) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The Company will lease an office at 25 N Market st, Jacksonville FL 32202 for \$957 USD per month.

## 7) Company Insiders (Officers, Directors, and Control Persons)

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% or more of any class of the issuer's securities, as well as any officer, and any director of the company, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

| Name of Officer/Director or Control Person | Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%) | Residential Address (City / State Only) | Number of shares owned | Share type/class   | Ownership Percentage of Class Outstanding | Note |
|--|---|---|------------------------|--------------------|---|------|
| Esau Delke                                 | CEO   | Jacksonville, FL                        | 100,000                | Series D Preferred | 100%                                      |      |

|       |       |       |       |       |       |       |
|-------|-------|-------|-------|-------|-------|-------|
| _____ | _____ | _____ | _____ | _____ | _____ | _____ |
| _____ | _____ | _____ | _____ | _____ | _____ | _____ |
| _____ | _____ | _____ | _____ | _____ | _____ | _____ |
| _____ | _____ | _____ | _____ | _____ | _____ | _____ |

## 8) Legal/Disciplinary History

A. Please identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

No

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

No

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

No

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

No

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

No

## 9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name: Don Keer  
Firm: \_\_\_\_\_  
Address 1: 3663 Greenwood Circle Chalfont, PA 18914  
Address 2: \_\_\_\_\_  
Phone: 215-962-9378  
Email: \_\_\_\_\_

Accountant or Auditor

Name: \_\_\_\_\_  
Firm: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

Investor Relations

Name: \_\_\_\_\_  
Firm: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period.

Name: \_\_\_\_\_  
Firm: \_\_\_\_\_  
Nature of Services: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_



## 10) Issuer Certification

### *Principal Executive Officer:*

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Esau David Delke certify that:

1. I have reviewed this Annual Report of Fuse Science, Inc. ;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

12 / 7 / 2022

Esau Delke / Esau Delke

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

### *Principal Financial Officer:*

I, Esau David Delke certify that:

1. I have reviewed this Annual Report of Fuse Science, Inc. ;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

12 / 7 / 2022

Esau Delke / Esau Delke

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

**Fuse Science, Inc.**  
**Notes to the Financial Statements**  
**For the year ended September 2022 (unaudited)**

**(1) LEGAL STATUS AND OPERATIONS**

Fuse Science, Inc. ("the Company") was incorporated in Nevada on September 21, 1988.

The Company, has developed and maintains Deskx AI, a cloud-based customer service platform with a primary focus on live video, remote assistance and computer vision for business of all sizes.

**(2) BASIS OF PREPARATION**

**2.1 Statement of compliance**

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") on a going concern.

**2.2 Accounting Convention**

These financial statements have been prepared on the basis of 'historical cost convention using accrual basis of accounting except as otherwise stated in the respective accounting policies notes.

**2.3 Going concern**

The accompanying unaudited financial statements have been prepared on the assumption that the Company will continue as a going concern. However, the Company does not have significant cash or other material assets, nor does it have an established source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. It is the intent of the Company to seek a merger with an existing, operating company. In the interim, shareholders of the Company have committed to meeting its minimal operating expenses.

In addition, the inability of The Company to become current in periodic reporting obligations under the federal securities laws during the fourth quarter limited the information that the Company was able to provide to the public, to investors and to other interested parties, including customers and certain lenders. Furthermore, such inability to become current limited the Company's ability to use equity incentives to attract, retain and motivate employees. Such inability to become current also restricted the Company's ability to raise capital through the issuance of equity or debt securities, use equity securities for acquisitions of complementary companies and businesses and engage in other strategic transactions.

**2.4 Critical accounting estimates and judgements**

The preparation of financial statements in conformity with the approved accounting standards require management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised if the revision affects only that period, or in the period of the revision and future periods.

The areas involving higher degree of judgment and complexity, or areas where assumptions and estimates made by the management are significant to the financial statements are as follows:

- i) Provision for income tax (note - 3.1)
- iii) Stock based compensation (note - 3.12)

### **3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

#### **3.1 Income tax**

The tax expense for the year comprises of income tax, and is recognized in the statement of earnings. The income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the balance sheet date. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation and establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

Deferred income tax is accounted for using the balance sheet liability method in respect of all temporary differences arising from differences between the carrying amount of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred income tax liabilities are recognised for all taxable temporary differences and deferred income tax assets are recognised to the extent that it is probable that taxable profits will be available against which the deductible temporary differences and unused tax losses can be utilized. Deferred income tax is calculated at the rates that are expected to apply to the period when the differences are expected to be reversed.

#### **3.2 Accounts payable**

Liabilities for trade and other amounts payable are carried at cost, which is the fair value of the consideration to be paid in future for goods and services received, whether or not billed to the Company.

#### **3.3 Provisions**

A provision is recognized in the financial statements when the Company has a legal or constructive obligation as a result of past events and it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of obligation.

#### **3.4 Accounts Receivable**

Accounts receivable are non-interest bearing obligations due under normal course of business. The management reviews accounts receivable on a monthly basis to determine if any receivables will be potentially uncollectible. Historical bad debts and current economic trends are used in evaluating the allowance for doubtful accounts. The Company includes any accounts receivable balances that are determined to be uncollectible in its overall allowance for doubtful accounts. After all attempts to collect a receivable have failed, the receivable is written off against the allowance. Based on the information available, the Company believes its allowance for doubtful accounts as of period ended is adequate.

### **3.5 Contingent liabilities**

A contingent liability is disclosed when the Company has a possible obligation as a result of past events, the existence of which will be confirmed only by the occurrence or non-occurrence, of one or more uncertain future events, not wholly within the control of the Company; or when the Company has a present legal or constructive obligation, that arises from past events, but it is not probable that an outflow of resources embodying economic benefits will be required to settle the obligation, or the amount of the obligation cannot be measured with sufficient reliability.

### **3.6 Financial liabilities**

Financial liabilities are recognized when the Company becomes party to the contractual provision of the instruments and the Company loses control of the contractual right that comprise the financial liability when the obligation specified in the contract is discharged, cancelled or expired. The Company classifies its financial liabilities in two categories: at fair value through profit or loss and financial liabilities measured at amortized cost. The classification depends on the purpose for which the financial liabilities were incurred. Management determines the classification of its financial liabilities at initial recognition.

#### **(a) *Financial liabilities at fair value through profit or loss***

Financial liabilities at fair value through profit or loss are financial liabilities held for trading. A financial liability is classified in this category if incurred principally for the purpose of trading or payment in the short-term. Derivatives (if any) are also categorized as held for trading unless they are designated as hedges.

#### **(b) *Financial liabilities measured at amortized cost***

These are non-derivative financial liabilities with fixed or determinable payments that are not quoted in an active market. These are recognized initially at fair value, net of transaction costs incurred and are subsequently stated at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the profit and loss account.

### **3.7 Cash and cash equivalents**

Cash and cash equivalents include cash in hand and deposits held at call with banks. For the purpose of the statement of cash flows, cash and cash equivalents bank balances and short term highly liquid investments subject to an insignificant risk of changes in value and with maturities of less than three months.

### **3.8 Revenue recognition**

Revenue is recognised to the extent it is probable that the economic benefits will flow to the Company and the revenue can be measured reliably. Revenue is measured at the fair value of the consideration received or receivable for goods sold or services rendered, net of discounts and sales tax and is recognised when significant risks and rewards are transferred.

### **3.9 Functional and presentation currency**

Items included in the financial statements are measured using the currency of the primary economic environment in which the Company operates. The financial statements are presented in US (Dollars) which is the Company's presentation currency. All financial information presented in US Dollars has been rounded to the nearest dollar unless otherwise stated.

### **3.10 Foreign currency transactions**

Foreign currency transactions are translated into the functional currency using the exchange rate prevailing on the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated into functional currency using the exchange rate prevailing at the statement

currencies are translated into functional currency using the exchange rate prevailing at the statement of financial position date. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates are recognized in the statement of operations.

### **3.11 Contingencies**

The assessment of the contingencies inherently involves the exercise of significant judgment as the outcome of the future events cannot be predicted with certainty. The Company, based on the availability of the latest information, estimates the value of contingent assets and liabilities, which may differ on the occurrence / non-occurrence of the uncertain future event(s).

### **3.12 Stock based compensation**

The Company recognizes compensation expense for stock-based compensation in accordance with generally accepted accounting principles. For employee stock-based awards, fair value of the award on the date of grant is calculated using the Black-Scholes method and the quoted price of the Company's common stock for stock options and unrestricted shares respectively;

The Company recognizes expense over the service period for awards expected to vest.

In case of non-employee stock-based awards, fair value of the award on the date of grant is calculated in the same manner as employee awards. However, the awards are revalued at the end of each reporting period and the pro rata compensation expense is adjusted accordingly until such time the nonemployee award is fully vested, at which time the total compensation recognized to date equals the fair value of the stock-based award as calculated on the measurement date, which is the date at which the award recipient's performance is complete. The estimation of stock-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised. We consider many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience.

The Black-Scholes option valuation model is used to estimate the fair value of the warrants or options granted. The model includes subjective input assumptions that can materially affect the fair value estimates. The model was developed for use in estimating the fair value of traded options or warrants. The expected volatility is estimated based on the most recent historical period of time equal to the weighted average life of the warrants or options granted.

Fuse Science, Inc.  
Balance Sheet  
As at September 30th 2022 (unaudited)

|  | Notes | As at September 30, 2021<br>(Unaudited)(\$) | As at September 30, 2022<br>(Unaudited)(\$) |   |
|--|-------|---|---|---|
| <b>ASSETS</b>  |       |   |   |   |
| <b>Current Assets</b>  |       |   |   |   |
| Cash and cash equivalents  | 4     | -   | 5,761.65                                    | - |
| Due from related parties   | 5     | -   |   | - |
| Investment in marketable securities  | 6     | -   |   |   |
| Prepaid expenses   | 7     |   |   | - |
| Other assets   |       | -   |   | - |
| <b>Total Current Assets</b>  |       | -   | 5,761.65                                    | - |
| Intellectual property, net   | 8     | -   |   | - |
| Property, plant and equipment, net   | 9     | -   |   | - |
| <b>Total Assets</b>  |       | -   | 5,761.65                                    | - |
| <b>EQUITY &amp; LIABILITIES</b>  |       |   |   |   |
| <b>Current Liabilities</b>   |       |   |   |   |
| Accounts payable   | 10    | -   |   | - |
| Notes payable - related party  |       | -   |   | - |
| Accrued expenses   | 11    | -   |   | - |
| <b>Total Current Liabilities</b>   |       | -   |   | - |
| Derivative liabilities   | 12    | -   |   | - |
| <b>Total Liabilities</b>   |       | -   |   | - |
| <b>SHAREHOLDER'S EQUITY</b>  |       |   |   |   |
| Preferred Stock - (\$.001 par value, 10,000,000 shares authorized)                       |       | -   |   | - |
| Series A - Convertible Preferred Stock - (\$.001 par value, 1,500,000 shares designated) |       | -   |   | - |
| Series B - Convertible Preferred Stock - (\$.001 par value, 3,200,000 shares designated) |       | -   |   | - |
| Series C - Convertible Preferred Stock - (\$.001 par value, 3,500,000 shares designated) |       | -   |   | - |
| Common stock (\$.0001 par value, 800,000,000 shares authorized)                          |       | -   |   | - |
| Additional paid in capital   |       | -   |   | - |
| Accumulated deficit  |       | -   |   | - |
| <b>Total Shareholders' Equity</b>  |       | -   |   | - |
| Non-controlling interest   |       | -   |   | - |
| <b>Total Liabilities and Equity</b>  |       | -   |   | - |
|  |       | -   |   | - |

Fuse Science, Inc.  
Consolidated Statement of Operations  
For the year ended September 30 2021 (unaudited)

| Notes   | For the year ended September 30, 2021 |  | For the year ended September 30, 2022 |   |
|---|---------------------------------------|--|---------------------------------------|---|
|   | ---- Amount in \$ ----                |  |                                       |   |
| SALES   | -                                     |  | 26,857.38                             | - |
| COST OF SALES   | -                                     |  | 152.15                                | - |
| GROSS PROFIT  | -                                     |  | 26,705.23                             | - |
| OPERATING EXPENSES                                    |                                       |  |                                       |   |
| Sales and marketing expense                           | -                                     |  | 6,231.48                              | - |
| General and administrative expense                    | -                                     |  | 14,712.1                              | - |
| Research and development                              | -                                     |  | -                                     | - |
| Loss on retirement of assets                          | -                                     |  | -                                     | - |
| TOTAL OPERATING EXPENSES                              | -                                     |  | 20,943.58                             | - |
| OPERATING PROFIT / (LOSS)                             | -                                     |  | -                                     | - |
| OTHER INCOME / (EXPENSE)                              |                                       |  |                                       |   |
| Interest expense                                      | -                                     |  | -                                     | - |
| Expense on issuance of warrant derivative liability   | -                                     |  | -                                     | - |
| Change in fair value of derivative liabilities        | -                                     |  | -                                     | - |
| Expense on inducement of warrant exchange             | -                                     |  | -                                     | - |
| Gain on debt extinguishment                           | -                                     |  | -                                     | - |
| PROFIT / (LOSS) BEFORE TAX                            | -                                     |  | 5,761.65                              | - |
| Taxes   | -                                     |  | -                                     | - |
| NET PROFIT / (LOSS)                                   | -                                     |  | -                                     | - |
| Net loss attributable to the non-controlling interest | -                                     |  | -                                     | - |
| Net loss attributable to common Shareholders          | -                                     |  | -                                     | - |

Fuse Science, Inc.  
Statement of cashflows  
As at September 30 2021 (unaudited)

|  | 2021 | 2022       |
|--|------|------------|
| Cash flow from operating activities                |      |            |
| (Loss) / profit before income tax                  | -    | 5,761.65   |
| Adjustment for non cash charges and other items    | -    | -          |
|  | -    | -          |
| Changes in operating assets                        |      |            |
| Decrease / (increase) in account receivable        | -    | -          |
| Decrease / (increase) in inventory                 | -    | -          |
| Decrease / (increase) in due from related party    | -    | -          |
| Decrease / (increase) in prepaid expenses          | -    | -          |
| Decrease / (increase) in other assets              | -    | -          |
| (Decrease) / increase in accounts payable          | -    | -          |
| (Decrease) / increase in accrued expenses          | -    | -          |
|  | -    | -          |
| Cash flow from operating activities                | -    | 5,761.65-  |
| Cash flow from investing activities                |      |            |
| Additions / disposal in intellectual properties    |      | -          |
| Additions in property, plant and equipment         |      | -          |
| Additions in investments                           |      | -          |
| Cash flow from / (used) in investing activities    |      | -          |
| Cash flow from financing activities                |      |            |
| Borrowings during / (repaid) the year              |      | -          |
| Proceeds from warrant exercise                     |      | -          |
| Issuance of share capital                          |      | -          |
| Cash flow from financing activities                |      | -          |
| Increase/(decrease) in cash and cash equivalents   |      | 5,761.65 - |
| Cash and cash equivalents at beginning of the year | -    | 0          |
| Cash and cash equivalents at end of the year       | -    | 5,761.65-  |
|  | -    |            |
|  | -    |            |



Fuse Science, Inc.  
Statement of Shareholders' Equity  
As at September 30 2022 (unaudited)

|                                     | Preferred Stock |     | Series A - Preferred Stock |     | Series B - Preferred Stock |     | Series C - Preferred Stock |     | Common Stock |     | Additonal Paid<br>in capital | Accumulated<br>Profit / (Deficit) | Non-controlling<br>interest | Total |
|-------------------------------------|-----------------|-----|----------------------------|-----|----------------------------|-----|----------------------------|-----|--------------|-----|------------------------------|-----------------------------------|-----------------------------|-------|
|                                     | Shares          | Par | Shares                     | Par | Shares                     | Par | Shares                     | Par | Shares       | Par |                              |                                   |                             |       |
| As at September 30 2021 (unaudited) | -               | -   | 1,500,000                  | -   | 3,200,000                  | -   | 3,500,000                  | -   | 80,000,000   | -   | -                            | -                                 | -                           | -     |
| Profit / (loss) for the period      |                 |     |                            |     |                            |     |                            |     |              |     |                              | -                                 | -                           | -     |
| As at September 30 2022 (unaudited) | -               | -   | 1,500,000                  | -   | 3,200,000                  | -   | 3,500,000                  | -   | 800,000,000  | -   | -                            | -                                 | -                           | -     |

4   **Cash and cash equivalents**

This represent cash in hand and cash deposited in bank accounts (current) by the Company.

Amount in \$  
5,761.65 \_

5   **Due from related parties**

|                                |   |
|--------------------------------|---|
| Opening balance                | - |
| Net movement during the period | - |
| Closing balance                | - |

6   **Investment in marketable securities**

|                                |   |
|--------------------------------|---|
| Opening balance                | - |
| Net movement during the period | - |
| Closing balance                | - |

7   **Prepaid expenses**

|                                |   |
|--------------------------------|---|
| Opening balance                | - |
| Net movement during the period | - |
| Closing balance                | - |

8   **Intellectual property, net**

|                                |   |
|--------------------------------|---|
| Opening balance                | - |
| Net movement during the period | - |
| Closing balance                | - |

9   **Property, plant and equipment, net**

|                           |   |
|---------------------------|---|
| Land and building (hotel) | - |
|---------------------------|---|

10   **Accounts payable**

|   |   |
|---|---|
| Opening balance                               | - |
| Net movement in liabilities during the period | - |
| Closing balance                               | - |

11   **Notes payable - related party**

|   |   |
|---|---|
| Opening balance                               | - |
| Net movement in liabilities during the period | - |
| Closing balance                               | - |

11   **Accrued expenses**

|   |   |
|---|---|
| Opening balance                               | - |
| Net movement in liabilities during the period | - |
| Closing balance                               | - |

Amount in \$

12   **Derivative liabilities**

|   |   |
|---|---|
| Opening balance                               | - |
| Net movement in liabilities during the period | - |
| Closing balance                               | - |

13   **Contingencies and Commitments**

From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As at the end of current reporting period, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of operations and there are no proceedings in which any directors, officers or affiliates, or any registered or beneficial stockholder, is an adverse party or has a material interest adverse to the Company's interest.

Chief Executive

*Esau Delke*

Director

*Esau Delke*